Astena Holdings (8095): FY2025 Results Summary — Record Profit at Every Level as Fine Chemicals Rebounds

This article is based on publicly available IR materials and is not a recommendation to buy or sell any specific securities.

Note: Astena Holdings Co., Ltd. does not publish an English results presentation; this article is based on the company’s Japanese-language results presentation, with figures transcribed as reported. The company’s fiscal year ends on November 30, and the period covered here is the fiscal year ended November 30, 2025, which the presentation itself labels FY2025.

Astena Holdings (8095), a Tokyo Stock Exchange Prime Market listed group spanning fine chemicals, health & beauty care and food, pharmaceuticals, industrial chemicals and social impact businesses, reported net sales of ¥62,744 million for FY2025, up 8.2% year on year. Operating profit rose 7.2% to ¥3,017 million and ordinary profit rose 3.8% to ¥2,910 million. Profit attributable to owners of parent came to ¥2,187 million, against a loss of ¥2,525 million a year earlier, as the impairment loss booked in the previous year did not recur and a gain on the sale of cross-shareholdings was recorded as extraordinary income. The presentation states that the company achieved record highs at every profit level.

Consolidated Results (Full-Year Actual)

The presentation attributes the increase in sales and operating profit mainly to the Fine Chemicals and HBC & Food segments. EBITDA, defined in the materials as operating profit plus depreciation, was ¥5,444 million, up 6.3%. ROE recovered to 8.4% from minus 9.4%, an improvement of 17.8 points. Against the revised full-year forecast disclosed on July 11, 2025, the company achieved 98% of the sales plan, 97% of operating profit, 100% of ordinary profit and 122% of net income; forecast ROE was 7.0%, which the actual result exceeded by 1.4 points.

Item	FY2025	FY2024	Change
Net sales (¥ million)	62,744	57,993	+4,750 (+8.2%)
Operating profit (¥ million)	3,017	2,815	+201 (+7.2%)
Ordinary profit (¥ million)	2,910	2,804	+106 (+3.8%)
Profit attributable to owners of parent (¥ million)	2,187	△ 2,525	+4,712 (—)
EBITDA (¥ million)	5,444	5,122	+322 (+6.3%)
ROE	8.4%	△9.4%	+17.8pt

Segment Results

Sales growth was led by the HBC & Food segment, mainly because the Ikeda Bussan group was consolidated as a subsidiary from the fourth quarter. Operating profit growth was driven by Fine Chemicals, which absorbed one-time costs in the Social Impact business and in adjustments. FY2024 segment figures are restated on the same corporate-cost allocation basis as FY2025. Operating margins in FY2025 were 4.1% for Fine Chemicals (up 3.0 points), 3.9% for HBC & Food (down 0.3 points), 9.0% for Medical (down 2.4 points), 7.5% for Industrial Chemicals (down 0.4 points) and minus 636.5% for Social Impact; the consolidated operating margin was 4.8%.

Segment	Net sales FY2025 (¥ million)	Net sales FY2024 (¥ million)	Operating profit FY2025 (¥ million)	Operating profit FY2024 (¥ million)
Fine Chemicals	22,333	21,127	909	219
HBC & Food	18,190	15,162	700	623
Medical	12,429	11,469	1,118	1,302
Industrial Chemicals	9,732	10,195	733	807
Social Impact	57	38	△ 363	△ 129
Adjustments	–	–	△ 80	△ 6
Consolidated	62,744	57,993	3,017	2,815

In Fine Chemicals, gross profit rose 25.7% to ¥4,097 million and the gross margin improved 2.9 points to 18.3%, lifting operating profit 314.5%. The presentation cites steady order intake for MicroED and nitrosamine-related work in the CMC field, steady orders for mid-molecule API process development in the peptide and nucleic acid field, profit contributions from imported APIs and intermediates for new drugs on improved margins, higher plant utilization after the introduction of a two-shift production system in formulation manufacturing, and strong high-value-added contract work in API manufacturing.

In HBC & Food, gross profit rose 21.7% to ¥8,602 million and the gross margin was 47.3%. The Food Ingredients division grew on higher demand for existing and high-margin products despite fewer new accounts, and earnings from the Ikeda Bussan group began to be consolidated from the fourth quarter. The Cosmetics Manufacturing & Sales division achieved a large increase in sales and profit helped by new product launches in the imported Korean cosmetics brand Torriden. One-time costs associated with the consolidation of the Ikeda Bussan group reduced profit in other items and adjustments. Astena acquired 95% of the shares of the Ikeda Bussan group, a company established in 1956 and headquartered in Yokohama with about 50 employees that imports and sells cosmetics ingredients and holds a 100% stake in IKEDA CORPORATION OF AMERICA.

In the Medical segment, gross profit rose 10.1% to ¥4,278 million but operating profit fell 14.1%. Sales of generic drugs competing with originator products designated under the selective medical treatment system were firm, while generics whose prices came to match or exceed originator prices after the NHI drug price revision were weak, and the continued suspension of production of some products due to raw material shortages weighed on the division. In the Aesthetic Medicine division, the NAVISION DR range of cosmetics sold exclusively through medical institutions continued to grow, and the illsera range, handled from 2025, sold ahead of plan.

In Industrial Chemicals, gross profit rose 1.8% to ¥3,852 million and the gross margin improved 2.5 points to 39.6%, but operating profit fell 9.2%. The Surface Treatment Chemicals division focused on high-value-added products such as chemicals for fine wiring formation, plating chemicals for passive components and chemicals for semiconductor electrode formation, and posted higher profit on new overseas customer acquisition. The Surface Treatment Equipment division saw equipment sales fall sharply as customers’ capital investment cycle ran its course. The two divisions combined increased profit excluding other items and adjustments, where higher management fees paid to the holding company reduced the segment result.

In the Social Impact business, sales rose 50% year on year to ¥57 million on wider distribution, but an operating loss of ¥363 million was recorded on up-front investment. The NAIA healthcare brand won the 2025 Good Design Award for four skincare products and grew sales through media exposure and e-commerce marketplaces while incurring product development and brand awareness costs. The Furusato NOW hometown tax payment platform grew sales 53% year on year and turned profitable on a standalone basis. The Noto SDGs Fund has 16 cumulative investments under way, and the Noto Beyond Reconstruction Fund made its first investment in NOTO Naorai, a sake brewery with a distillery in Noto.

FY2026 Forecast

For the fiscal year ending November 30, 2026, Astena forecasts higher sales led by the HBC & Food segment and is targeting record highs at every profit level. The presentation attributes the 12.7% forecast increase in operating profit to growth centered on Fine Chemicals and to the absence of the one-time costs booked at the holding company and elsewhere in the previous year.

Item	FY2026 Forecast	FY2025 (Actual)	Change
Net sales (¥ million)	68,000	62,744	+5,255 (+8.4%)
Operating profit (¥ million)	3,400	3,017	+382 (+12.7%)
Ordinary profit (¥ million)	3,300	2,910	+389 (+13.4%)
Profit attributable to owners of parent (¥ million)	2,350	2,187	+162 (+7.5%)
ROE	8.5%	8.4%	+0.1pt

Shareholder Returns

Astena’s basic dividend policy is to provide stable, performance-linked returns with a dividend on equity ratio (DOE) of 1.5% as a floor and a consolidated payout ratio of around 30% as a guide. For FY2026 the company forecasts an interim dividend of ¥9 and a year-end dividend of ¥9, for an annual total of ¥18 per share. Among capital-efficiency measures, the company is reducing cross-shareholdings: it cut a cumulative ¥1,505 million over the five years through FY2025, or approximately ¥1.5 billion, with the number of issues held falling from 38 to 32, and it plans to reduce the balance to less than 10% of consolidated net assets by the end of FY2027. The presentation also states that flexible share buybacks are under consideration.

Item	FY2026
Interim dividend per share (forecast)	¥9
Year-end dividend per share (forecast)	¥9
Annual dividend per share (forecast)	¥18
Dividend on equity (DOE)	1.5% or above
Consolidated payout ratio	around 30%

Medium-Term Plan and Topics

Astena is rolling forward a three-year medium-term management plan covering 2026 to 2028 on the way to its Astena 2030 long-term vision. The medium-term plan targets net sales of ¥76 billion, operating profit of ¥4 billion and ROE of 9.0% in FY2028, while the long-term vision for FY2030 targets net sales of ¥90 billion and ROE of 13.0%. The company identifies a price-to-book ratio below one as a key management issue, noting that PBR has improved in line with ROE but has continued to trade below one times, and it aims to improve profitability, capital efficiency and market valuation together. Specific measures listed are strengthening earnings power and executing growth investment in the Fine Chemicals, HBC & Food and Social Impact areas; optimizing capital efficiency through the reduction of cross-shareholdings and stable dividends alongside flexible buybacks; and strengthening dialogue with investors through a dedicated IR organization together with expanded non-financial disclosure.

Since 2019 the group has sold non-core businesses and assets and withdrawn from certain businesses while executing more than ¥20 billion of strategic investment, including M&A, in focus areas, with the acquisition of the Ikeda Bussan group among the items listed for FY2025. On ESG, the company was rated B- in the climate change assessment by CDP, an improvement on the prior year, and introduced a special incentive scheme through the group employee shareholding association under which shares worth about ¥90 million were granted to 814 members, raising the participation rate by about 30 points. The company also newly established a set of group action guidelines and began disclosing third-quarter results presentation materials and a spreadsheet-based DATABOOK.

This article is an analysis based on publicly available information and is not a recommendation to buy or sell any specific securities. Investment decisions are your own responsibility.